2025-09-19 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the provided data, presented in English with a focus on key metrics and their implications:

## TMDX (TransMedics Group Inc.) Stock Analysis

**Company Overview:** TransMedics Group Inc. is a medical technology company pioneering the Organ Care System (OCS) for preserving and assessing organs for transplant.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return:**
    *   TMDX: 230.88%
    *   VOO: 77.57%
    *   **Difference: 137.2**
*   **Relative Difference:** 55.9 (This indicates that TMDX's current outperformance is in the 55.9th percentile of its historical range relative to VOO.)

**Analysis:** TMDX has significantly outperformed the S&P 500.  A relative difference of 55.9 suggests the outperformance is substantial but not at the extreme high end of its historical range compared to VOO. The data suggests the current difference (137.2) is closer to the average than the maximum difference.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha | Beta | Cap(B) |
|------------|---------|-------|-------|------|--------|
| 2019-2021  | -4.0%   | 63.4% | -52.0%| 0.0  | 0.7    |
| 2020-2022  | 140.0%  | 68.3% | 138.0%| 0.1  | 2.1    |
| 2021-2023  | 95.0%   | 69.4% | 77.0% | 0.2  | 2.7    |
| 2022-2024  | 147.0%  | 82.8% | 121.0%| 0.2  | 2.1    |
| 2023-2025  | 112.0%  | 82.8% | 54.0% | 0.5  | 4.1    |

**Analysis:**

*   **CAGR:**  Strong growth in recent periods (2020-2025).
*   **MDD:**  High Maximum Drawdown (MDD) indicates significant volatility and risk.
*   **Alpha:**  High Alpha values show significant outperformance compared to the market.
*   **Beta:**  Beta is increasing, showing the stock becomes more correlated with the market.
*   **Cap:**  Market Capitalization is consistently increasing, reflecting the growing size of the company.

### 2. Recent Stock Price Movement

*   **Current Price:** 121.10
*   **Previous Close:** 119.81
*   **Change:** 1.08
*   **5-day Moving Average:** 117.78
*   **20-day Moving Average:** 113.46
*   **60-day Moving Average:** 117.92

**Analysis:**  The current price is above all moving averages, suggesting an upward trend.  The price has recently increased relative to the previous close. The 20-day moving average is below the 60-day moving average.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 56.05 (Neutral)
*   **PPO:** 1.28 (Indicates upward trend)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (4 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** 2.1 (+): Short-term increase
*   **Expected Return:** 78.7% (Long-term, relative to S&P 500)

**Analysis:**

*   The **low MRI** suggests that the stock is considered relatively safe.
*   The **RSI** is in a neutral zone, not indicating overbought or oversold conditions.
*   **PPO** indicates upward trend.
*   The **Hybrid Signal** suggests a buy signal (using 80% of available cash), but with caution due to the MRI (though the MRI is low, the signal highlights it).
*   The positive **Delta_Previous_Relative_Divergence** confirms a recent upward trend relative to the S&P 500.
*   The **Expected Return** is very high, indicating strong confidence in the company's long-term growth potential compared to the broader market.

Given the change of 1.08, there's a positive movement, it's not a dramatic jump, but it confirms the upward trend.

### 4. Recent News & Significant Events

*   **Analyst Target Price Increase (Argus Research):**  Target price raised to $125.
*   **Insider Buying:**  Increased insider holdings suggest confidence in the company's future.
*   **Wall Street Bullish Sentiment:** Multiple articles highlight positive analyst outlooks and long-term growth potential.
*   **Stifel Initiation:**  Neutral rating with a $115 price target.

**Analysis:** The news flow is predominantly positive.  The target price increase is a strong signal. Insider buying is generally considered a positive indicator. Analyst bullishness further supports a positive outlook.  The Stifel initiation provides a more balanced view.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (1.70)
*   **Target Price (avg/high/low):** 140.67 / 170.00 / 114.00

**Analysis:** Analyst consensus is strongly positive, with a "Buy" rating. The average target price suggests significant upside potential from the current price.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 예상 EPS |
|------------|------|----------|
| 2025-07-30 | 0.92 | 0.48     |
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |

**Analysis:** The company has consistently beaten EPS estimates in recent quarters, demonstrating strong financial performance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $0.16B     | 61.38%        |
| 2025-03-31 | $0.14B     | 61.47%        |
| 2024-12-31 | $0.12B     | 59.21%        |
| 2024-09-30 | $0.11B     | 55.94%        |
| 2024-06-30 | $0.11B     | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-06-30 | $0.32B     | 10.97% |
| 2025-03-31 | $0.27B     | 9.64%  |
| 2024-12-31 | $0.23B     | 3.00%  |
| 2024-09-30 | $0.21B     | 2.01%  |
| 2024-06-30 | $0.19B     | 6.42%  |

**Analysis:**

*   **Revenue:**  Consistent revenue growth quarter-over-quarter.
*   **Profit Margin:**  Very high and stable profit margins indicate a strong business model.
*   **Equity:**  Growing equity suggests strong capital accumulation.
*   **ROE:**  Increasing Return on Equity (ROE) demonstrates improving profitability and efficiency.

### 7. Overall Summary

TransMedics Group Inc. (TMDX) presents a compelling investment case based on the provided data.

*   **Strong Performance:**  Significant outperformance compared to the S&P 500, with high Alpha values.
*   **Growth:**  Consistent revenue and earnings growth, with increasing profitability.
*   **Positive Sentiment:**  Bullish analyst ratings, target price increases, and insider buying.
*   **Risk:**  High MDD indicates significant volatility.
*   **Future Potential:** High expected return, driven by innovative technology and market leadership.

**Overall Recommendation:** While the high volatility (MDD) should be noted, the positive trends in revenue, profitability, earnings, and analyst sentiment suggest a positive outlook for TMDX. The stock appears to be a strong growth opportunity.
